iQSTEL (IQST) Q4 2025 Earnings Transcript

iQSTEL reported 2025 revenue of about $316.9 million, up 11.9% year over year, with adjusted EBITDA above $2.7 million and gross margin improving from 2.74% to 3.46%. Management highlighted a $400 million revenue run rate, a goal to reach $1 billion in revenue within 24 months, and planned acquisitions that could add $5 million-$6 million of EBITDA each. The company is also pushing new high-margin verticals, including AI, cybersecurity, and a digital health MOU with a Taiwan partner, while targeting roughly $500,000 in annual cost savings from platform consolidation.

Analysis

The equity story is shifting from “can they grow?” to “can they actually capture economics from growth?” The cleanest second-order signal is the push to collapse minority interests and unify platforms: that is less about optics than about eliminating leakage, improving routing efficiency, and converting intercompany activity into controllable EBITDA. If executed, the company’s reported margin profile should improve faster than top-line growth, because the next leg is coming from operating leverage, not just volume.

The market is likely underestimating the execution risk embedded in the acquisition and integration plan. Management is talking about a large share of revenue/EBITDA moving onto one platform within a year, but telecom integrations usually create a lag between accounting synergies and cash synergies; any slip will hit a small-cap name with thin liquidity disproportionately hard. The near-term catalyst is the stated 40-day launch cadence on digital health/cybersecurity, but the real test is whether those launches produce paid conversions from the existing operator base rather than press-release revenue.

The contrarian angle is that the company may be less a telecom operator and more an underappreciated distribution rail into niche B2B verticals. That makes the upside asymmetric if even one of the new verticals gains traction, because the incremental customer acquisition cost is low and the addressable base is already “pre-sold” via operator relationships. But that same narrative can get ahead of itself quickly: if acquisition earnouts, proxy approvals, or integration hiccups stretch timelines, the stock can de-rate on credibility rather than fundamentals.

For now, the setup is best treated as a catalyst-driven microcap with potential multiple expansion, not a clean compounder. The key inflection points over the next 1-2 quarters are completion of minority buyouts, evidence of margin expansion without working-capital strain, and proof that the new verticals are monetizing through existing channels. If those don’t materialize, the equity is likely to revert to being valued on noisy, low-quality telecom revenue rather than platform optionality.

Key Decisions for Investors

• Long IQST as a small starter position ahead of the next 1-2 quarters of integration and product-launch catalysts; use a tight risk budget because the upside is tied to multiple expansion if EBITDA converts faster than expected.
• Pair trade: long IQST / short a broader telecom services or microcap basket to isolate platform-synergy upside from sector beta; thesis works best if operating leverage shows up before new-vertical revenue does.
• Buy out-of-the-money IQST calls only if liquidity allows and only into confirmed announcements on the minority-interest buyouts or first commercial launch; otherwise implied volatility is likely too expensive relative to realization risk.
• If IQST rallies hard on headline M&A or digital health news without a visible revenue bridge, fade strength by trimming or shorting into the move; the key risk is narrative outrunning monetization.
• Track CYCUW as a speculative expression of the cybersecurity cross-sell story, but size minimally; it is a lower-quality way to express the same thesis and is more dependent on partner execution than on IQST core economics.